CIBC World Markets Inc. lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 21.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 754,584 shares of the biopharmaceutical company’s stock after selling 200,321 shares during the period. CIBC World Markets Inc. owned approximately 0.06% of Gilead Sciences worth $53,409,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Harel Insurance Investments & Financial Services Ltd. increased its position in shares of Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 1,400 shares during the period. Penserra Capital Management LLC increased its position in shares of Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 144 shares during the period. American Beacon Advisors Inc. bought a new position in Gilead Sciences in the first quarter valued at about $143,000. Sterling Investment Advisors Ltd. bought a new position in Gilead Sciences in the second quarter valued at about $184,000. Finally, Truepoint Inc. bought a new position in Gilead Sciences in the second quarter valued at about $204,000. Institutional investors own 74.62% of the company’s stock.
Gilead Sciences, Inc. (NASDAQ:GILD) opened at $71.15 on Wednesday. The stock has a market capitalization of $92,920.00, a price-to-earnings ratio of 7.60, a price-to-earnings-growth ratio of -1.22 and a beta of 1.13. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $86.27.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.13 by $0.14. The firm had revenue of $6.51 billion during the quarter, compared to the consensus estimate of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The business’s revenue for the quarter was down 13.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.75 EPS. equities research analysts expect that Gilead Sciences, Inc. will post 8.53 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be paid a $0.52 dividend. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.92%. Gilead Sciences’s dividend payout ratio (DPR) is presently 23.66%.
ILLEGAL ACTIVITY NOTICE: “Gilead Sciences, Inc. (GILD) Position Lowered by CIBC World Markets Inc.” was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://sportsperspectives.com/2017/11/15/gilead-sciences-inc-gild-position-lowered-by-cibc-world-markets-inc.html.
In other news, CFO Robin L. Washington sold 51,820 shares of the company’s stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the transaction, the chief financial officer now owns 43,352 shares of the company’s stock, valued at approximately $3,684,920. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $75.13, for a total value of $5,509,508.29. Following the transaction, the insider now directly owns 3,070,099 shares in the company, valued at approximately $230,656,537.87. The disclosure for this sale can be found here. Insiders sold a total of 446,819 shares of company stock valued at $36,269,486 in the last 90 days. Corporate insiders own 1.30% of the company’s stock.
A number of research firms have issued reports on GILD. ValuEngine upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Thursday, September 7th. Zacks Investment Research cut Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Monday, September 11th. TheStreet upgraded Gilead Sciences from a “c+” rating to a “b-” rating in a research report on Thursday, September 7th. Vetr cut Gilead Sciences from a “buy” rating to a “hold” rating and set a $86.44 target price on the stock. in a research report on Monday, September 4th. Finally, Morgan Stanley reiterated an “equal weight” rating and issued a $83.00 target price (up previously from $77.00) on shares of Gilead Sciences in a research report on Friday, October 6th. One analyst has rated the stock with a sell rating, twelve have issued a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the stock. Gilead Sciences currently has an average rating of “Buy” and a consensus price target of $84.87.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.